NASDAQ:IMA ImageneBio (IMA) Stock Price, News & Analysis $5.94 -0.06 (-1.00%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$6.06 +0.12 (+2.02%) As of 06/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About ImageneBio Stock (NASDAQ:IMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImageneBio alerts:Sign Up Key Stats Today's Range$5.75▼$6.0950-Day Range$5.25▼$6.0852-Week Range$3.94▼$18.00Volume13,747 shsAverage Volume14,617 shsMarket Capitalization$63.26 millionP/E RatioN/ADividend YieldN/APrice Target$26.50Consensus RatingHold Company Overview ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. Read More ImageneBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreIMA MarketRank™: ImageneBio scored higher than 58% of companies evaluated by MarketBeat, and ranked 654th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingImageneBio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialImageneBio has a consensus price target of $26.50, representing about 346.1% upside from its current price of $5.94.Amount of Analyst CoverageImageneBio has only been the subject of 1 research reports in the past 90 days.Read more about ImageneBio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ImageneBio are expected to grow in the coming year, from ($3.66) to ($2.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImageneBio is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImageneBio is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImageneBio has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.80% of the float of ImageneBio has been sold short.Short Interest Ratio / Days to CoverImageneBio has a short interest ratio ("days to cover") of 24.12, which indicates bearish sentiment.Change versus previous monthShort interest in ImageneBio has recently decreased by 11.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImageneBio does not currently pay a dividend.Dividend GrowthImageneBio does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.93 News SentimentImageneBio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ImageneBio this week, compared to 2 articles on an average week.Search Interest1 people have searched for IMA on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImageneBio insiders have not sold or bought any company stock.Percentage Held by Insiders2.22% of the stock of ImageneBio is held by insiders.Percentage Held by Institutions75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ImageneBio's insider trading history. Receive IMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImageneBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMA Stock News HeadlinesImageneBio, Inc. Common Stock (IMA) SEC FilingsJune 25 at 3:22 PM | nasdaq.comImageneBio Shareholders Back Directors and Governance ProposalsJune 17, 2026 | tipranks.comTrump’s Dollar ResetPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.June 26 at 1:00 AM | Porter & Company (Ad)ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New YorkMay 27, 2026 | globenewswire.comImageneBio (IMA) price target decreased by 18.75% to 13.26May 15, 2026 | msn.comImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program UpdateMay 7, 2026 | globenewswire.comImageneBio Inc.April 13, 2026 | barrons.comIMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally?April 13, 2026 | msn.comSee More Headlines IMA Stock Analysis - Frequently Asked Questions How have IMA shares performed this year? ImageneBio's stock was trading at $6.90 on January 1st, 2026. Since then, IMA stock has decreased by 13.9% and is now trading at $5.94. How were ImageneBio's earnings last quarter? ImageneBio, Inc. (NASDAQ:IMA) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.25. When did ImageneBio's stock split? ImageneBio's stock reverse split on Monday, July 28th 2025.The 1-12 reverse split was announced on Friday, July 25th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are ImageneBio's major shareholders? ImageneBio's top institutional investors include BML Capital Management LLC (1.88%), Renaissance Technologies LLC (0.77%) and Rangeley Capital LLC (0.31%). Insiders that own company stock include Otello Stampacchia and Joseph P Slattery. View institutional ownership trends. How do I buy shares of ImageneBio? Shares of IMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today6/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (32m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 IMA's financial health is in the Red zone, according to TradeSmith. IMA has been in this zone for over 32 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMA Previous SymbolNASDAQ:IMA CIK1835579 Webikenaoncology.com Phone857-273-8343FaxN/AEmployees70Year Founded2016Price Target and Rating Average Price Target for ImageneBio$26.50 High Price Target$30.00 Low Price Target$23.00 Potential Upside/Downside+346.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($5.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.35 million Net MarginsN/A Pretax Margin-5,712.38% Return on Equity-38.96% Return on Assets-34.60% Debt Debt-to-Equity RatioN/A Current Ratio18.39 Quick Ratio18.39 Sales & Book Value Annual Sales$800 thousand Price / Sales79.08 Cash FlowN/A Price / Cash FlowN/A Book Value$11.91 per share Price / Book0.50Miscellaneous Outstanding Shares10,650,000Free Float10,417,000Market Cap$63.26 million OptionableNot Optionable Beta0.72 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:IMA) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our Partners3 Wall St. Legends Have Same Dark Prediction for June 29thThree Wall Street legends are pointing to the same date - June 29th - as a potential turning point driven by a...TradeSmith | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredSpaceX IPO “cancelled”?SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...InvestorPlace | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe EPA just put a kill switch on Elon’s empireA federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...Behind the Markets | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
